CRIS Current Research Information System

SARTOR, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.439
NA - Nord America 4.869
EU - Europa 3.754
AF - Africa 378
SA - Sud America 306
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 8
Totale 15.764
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.790
VN - Vietnam 2.138
SG - Singapore 1.568
CN - Cina 1.468
IT - Italia 854
GB - Regno Unito 755
DE - Germania 462
SE - Svezia 462
HK - Hong Kong 382
FR - Francia 240
IN - India 219
KR - Corea 208
BR - Brasile 204
NL - Olanda 188
RU - Federazione Russa 154
FI - Finlandia 141
IE - Irlanda 133
JP - Giappone 103
ZA - Sudafrica 90
TG - Togo 82
CI - Costa d'Avorio 70
EE - Estonia 54
SC - Seychelles 54
NG - Nigeria 53
CA - Canada 45
JO - Giordania 45
BG - Bulgaria 44
UA - Ucraina 41
AR - Argentina 40
CH - Svizzera 39
PH - Filippine 38
ID - Indonesia 35
TH - Thailandia 33
IQ - Iraq 31
PL - Polonia 30
BE - Belgio 29
BD - Bangladesh 28
AT - Austria 27
ES - Italia 27
TR - Turchia 25
MX - Messico 23
TW - Taiwan 22
IR - Iran 17
PK - Pakistan 14
EC - Ecuador 13
GR - Grecia 13
UZ - Uzbekistan 13
VE - Venezuela 11
CL - Cile 9
LT - Lituania 9
PY - Paraguay 9
AU - Australia 8
PE - Perù 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
EU - Europa 6
MA - Marocco 6
MY - Malesia 6
PT - Portogallo 6
RO - Romania 6
RS - Serbia 6
CZ - Repubblica Ceca 5
HR - Croazia 5
LB - Libano 5
MK - Macedonia 5
SA - Arabia Saudita 5
AL - Albania 4
EG - Egitto 4
IL - Israele 4
KZ - Kazakistan 4
NP - Nepal 4
UY - Uruguay 4
BY - Bielorussia 3
HU - Ungheria 3
OM - Oman 3
QA - Qatar 3
DZ - Algeria 2
GY - Guiana 2
KE - Kenya 2
KG - Kirghizistan 2
LI - Liechtenstein 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
SO - Somalia 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
HN - Honduras 1
Totale 15.745
Salva come PNG Salva come JPEG
Città #
Singapore 1.106
Southend 663
Ashburn 621
Ho Chi Minh City 460
Chandler 429
Dong Ket 418
Hanoi 393
Hong Kong 352
Hefei 325
San Jose 298
Fairfield 271
Beijing 218
Ann Arbor 180
Seoul 180
Santa Clara 169
Bologna 163
Houston 161
Dallas 154
Wilmington 148
Woodbridge 145
Princeton 134
Dublin 133
Boardman 122
Seattle 122
Helsinki 106
Cambridge 98
Tokyo 85
Lauterbourg 84
Lomé 82
Milan 82
New York 82
Abidjan 70
Los Angeles 66
Haiphong 57
Frankfurt am Main 56
Nanjing 55
Westminster 55
Padova 52
Council Bluffs 50
Munich 49
Abeokuta 47
Da Nang 46
Medford 44
Sofia 44
São Paulo 44
Amman 41
Rome 40
Berlin 38
Buffalo 37
Bremen 36
Redondo Beach 35
Johannesburg 31
Bengaluru 30
Brussels 29
Redmond 29
Shanghai 29
Florence 28
Saint Petersburg 27
Bern 26
Redwood City 26
Shenyang 26
London 25
San Diego 25
Turin 25
Biên Hòa 24
Guangzhou 24
Jinan 24
Tianjin 24
Changsha 23
Zhengzhou 22
Toronto 21
Hebei 20
Thái Nguyên 20
Jakarta 19
Nanchang 19
Orem 19
Baghdad 18
Falkenstein 18
Hải Dương 18
Turku 18
Ha Long 17
Jiaxing 17
Nuremberg 17
Vienna 17
Chicago 16
Can Tho 15
Lappeenranta 15
Stockholm 15
Warsaw 15
Amsterdam 14
Phoenix 14
Wuhan 13
Atlanta 12
Bangkok 12
Fuzhou 12
Mountain View 12
Chengdu 11
Falls Church 11
Madrid 11
Ninh Bình 11
Totale 9.910
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 656
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 311
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 274
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 258
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 253
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 251
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 248
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 239
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 232
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 230
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 227
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 225
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 224
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 223
A case report of acute myeloid leukemia and neurofibromatosis 1 220
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 209
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 208
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 200
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 198
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 197
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 195
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 191
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 190
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 189
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 188
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 186
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 185
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 184
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 182
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 181
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia 180
Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study 179
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 176
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 175
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 174
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 172
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 172
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 171
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 170
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 169
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 166
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 166
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 166
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 165
Management of patients with chronic rhinosinusitis with nasal polyps (CRSwNP): Results from a survey among allergists and clinical immunologists of the North-west and Center Italy Inter-Regional Sections of SIAAIC and otorhinolaryngologists of National IAR 165
INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia 163
NEXT GENERATION SEQUENCING FOR MINIMAL RESIDUAL DISEASE MEASUREMENT IN THE DAILY CLINICAL MANAGEMENT OF PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS FEASIBLE AND PROVIDES USEFUL CLINICAL DATA. 163
SNP array reveals a new deletion of JAK2 in AML patients 162
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 161
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure 158
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 157
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease 156
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 155
HIGH RATE OF COMPLETE HEMATOLOGICAL RESPONSE IN ELDERLY PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS BY INNOVATIVE SEQUENTIAL USE OF NILOTINIB AND IMATINIB: A GIMEMA CLINICAL TRIAL LAL 1408 154
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 154
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 154
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 152
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 150
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 150
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 149
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 146
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 146
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 145
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia 145
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 144
Nelarabine front-line therapy for adult T-Lymphoblastic leukaemia/Lymphoma (T-LBL/ALL): preliminary results of a single centre experience 142
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 140
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 139
Emergence and Cytogenetic Clonal Evolution of Chromosome 7 Abnormalities in Myeloid Malignancies: Investigating the Role of Telomere Dysfunction 136
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 134
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study 132
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 130
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 130
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 128
Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience 127
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 125
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 123
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 122
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 121
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 120
MPN-182 Droplet Digital PCR for Non-Invasive Detection of the KIT D816V Mutation in the Peripheral Blood of Patients With Suspected Systemic Mastocytosis 119
Nelarabine front-line therapy for adult T-lymphoblastic leukemia/lymphoma (T-LBL/ALL): preliminary results of a single center experience. 119
Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis 118
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents 117
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 113
COMPARISON BETWEEN NGS IGH/TCR AND RT-PCR BCR::ABL1 MINIMAL RESIDUAL DISEASE IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA: A PRELIMINARY ANALYSIS 111
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 111
Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin 82
Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment 82
Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia 74
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 74
Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule 70
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 63
Rationale for a Pediatric-Inspired Approach in the Adolescent and Young Adult Population with Acute Lymphoblastic Leukemia, with a Focus on Asparaginase Treatment 59
null 52
null 50
Acute myeloid leukemia mutations: Therapeutic implications 50
Posterior Reversible Encephalopathy Syndrome in a B-Cell Acute Lymphoblastic Leukemia Young Adult Patient Treated with a Pediatric-like Chemotherapeutic Schedule 46
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 37
Totale 16.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.418
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.418
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021674 0 0 0 0 0 0 0 0 0 30 66 578
2021/20221.506 140 35 69 141 137 65 33 117 69 125 322 253
2022/20231.841 184 254 74 235 197 154 49 115 310 45 137 87
2023/2024602 16 73 38 62 38 118 43 62 31 39 53 29
2024/20252.662 113 361 212 207 245 122 268 113 48 264 209 500
2025/20266.376 620 1.159 498 483 614 305 586 248 1.440 423 0 0
Totale 16.080